Salt Lake City-based spinal device company Innovasis, Inc. has signed a private label agreement with Stability Biologics, LLC, a Nashville-based company that will provide Innovasis with a line of bone allograft tissue products.
Innovasis Partners With Stability Biologics
1 min read Premium comments
Secondary#innovasis#bonetissueallograft#stabilitybiologics
The private label agreement will allow Innovasis to commercialize, among other products, Stability’s flagship product, the Physio brand of human bone allograft.
Physio is a physiologic bone tissue allograft processed using a patent-pending process that allows Physio to remain 100% donated human cortical bone tissue with no added carrier, thus maximizing the amount of endogenous bone growth factors—such as BMP 2, 4, 7 (bone morphogenetic protein) and VEGF (vascular endothelial growth factor), osteogenic proteins, and biologic calcium phosphate minerals.
Furthermore, Physio’s microstructure offers superior handling, injection and moldability, as well as exceptional wet field integrity, stability and retention of the graft in the surgical field.
Innovasis expects its private labeled, Stability processed product lines to be available by December 2018.
Innovasis is known for its spinal product line with implants and instruments that address the major pathologies and focus areas of traditional spinal surgery. Innovasis is involved in the research, development, manufacturing, and marketing of spinal implant devices and related products. Stability is known for its human allograft tissue products available for the spine, orthopedics, and wound care.
Innovasis Director of Business Development and Clinical Affairs David Oka said, “We are excited to begin a strategic partnership with Stability Biologics which will provide Innovasis’ customers with a robust biologics platform to complement our instrumentation portfolio…. We anticipate Physio’s differentiated osteogenic microstructure will provide a potent ecosystem when used with our PEEK-OPTIMA HA Enhanced interbody platform.”
Stability CEO Brian Martin announced, “The potential for working with a company like Innovasis is very exciting…. We foresee the opportunity of a truly synergistic partnership with our respective companies given our innovative allograft tissue products combined with Innovasis’ revolutionary product offerings allowing us both to increase our respective customer base.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.